Cytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model

Besser, 2013, Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies, Clin. Cancer Res., 19, 4792, 10.1158/1078-0432.CCR-13-0380 Dudley, 2002, Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, Science, 298, 850, 10.1126/science.1076514 Gong, 2018, Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations, J. Immunother. Cancer, 6, 8, 10.1186/s40425-018-0316-z Iiyama, 2007, WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma, Microbiol. Immunol., 51, 519, 10.1111/j.1348-0421.2007.tb03940.x Ikeda, 2015, Determination of HLA-A, -C, -B, -DRB1 allele and haplotype frequency in Japanese population based on family study, Tissue Antigens, 85, 252, 10.1111/tan.12536 Inoue, 2017, Patient-derived xenografts as in vivo models for research in urological malignancies, Nat. Rev. Urol., 14, 267, 10.1038/nrurol.2017.19 June, 2018, Chimeric antigen receptor therapy, N. Engl. J. Med., 379, 64, 10.1056/NEJMra1706169 Klebanoff, 2016, Prospects for gene-engineered T cell immunotherapy for solid cancers, Nat. Med., 22, 26, 10.1038/nm.4015 Maeda, 2016, Regeneration of CD8αβ T cells from T-cell-derived iPSC imparts potent tumor antigen-specific cytotoxicity, Cancer Res., 76, 6839, 10.1158/0008-5472.CAN-16-1149 1999, Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators, Lancet, 353, 14, 10.1016/S0140-6736(98)03544-2 Minagawa, 2018, Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy, Cell Stem Cell, 23, 850, 10.1016/j.stem.2018.10.005 Morgan, 2006, Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, 314, 126, 10.1126/science.1129003 Motzer, 2015, Nivolumab versus everolimus in advanced renal-cell carcinoma, N. Engl. J. Med., 373, 1803, 10.1056/NEJMoa1510665 Motzer, 2018, Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, N. Engl. J. Med., 378, 1277, 10.1056/NEJMoa1712126 Nakatsuka, 2006, Immunohistochemical detection of WT1 protein in a variety of cancer cells, Mod. Pathol., 19, 804, 10.1038/modpathol.3800588 O'Reilly, 2016, Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections, Bone Marrow Transpl., 51, 1163, 10.1038/bmt.2016.17 Okita, 2011, A more efficient method to generate integration-free human iPS cells, Nat. Methods, 8, 409, 10.1038/nmeth.1591 Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer, 12, 252, 10.1038/nrc3239 Pavia-Jimenez, 2014, Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing, Nat. Protoc., 9, 1848, 10.1038/nprot.2014.108 Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N. Engl. J. Med., 365, 725, 10.1056/NEJMoa1103849 Pyrhonen, 1999, Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer, J. Clin. Oncol., 17, 2859, 10.1200/JCO.1999.17.9.2859 Qasim, 2017, Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells, Sci. Transl Med., 9, eaaj2013, 10.1126/scitranslmed.aaj2013 Radvanyi, 2012, Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients, Clin. Cancer Res., 18, 6758, 10.1158/1078-0432.CCR-12-1177 Rosenberg, 2015, Adoptive cell transfer as personalized immunotherapy for human cancer, Science, 348, 62, 10.1126/science.aaa4967 Rosenberg, 2011, Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy, Clin. Cancer Res., 17, 4550, 10.1158/1078-0432.CCR-11-0116 Sugita, 2016, Successful transplantation of retinal pigment epithelial cells from MHC homozygote iPSCs in MHC-matched models, Stem Cell Rep., 7, 635, 10.1016/j.stemcr.2016.08.010 Sugita, 2016, Lack of T Cell response to iPSC-derived retinal pigment epithelial cells from HLA homozygous donors, Stem Cell Reports, 7, 619, 10.1016/j.stemcr.2016.08.011 Tawara, 2017, Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS, Blood, 130, 1985, 10.1182/blood-2017-06-791202 Themeli, 2013, Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy, Nat. Biotechnol., 31, 928, 10.1038/nbt.2678 Vizcardo, 2013, Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8+ T cells, Cell Stem Cell, 12, 31, 10.1016/j.stem.2012.12.006